Covered recipient · General Payments record
JONATHAN S ILOWITE
Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$1,849.01
1 record · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,849.01 | 1 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,849.01 | 1 |
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JONATHAN S ILOWITE
NPI 1356403364 · CMS profile ID 288011
Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease
NEW HYDE PARK, NY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1356403364?year=2020&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JONATHAN S ILOWITE, NPI 1356403364, CMS profile ID 288011. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356403364?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). JONATHAN S ILOWITE, NPI 1356403364, CMS profile ID 288011. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356403364?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- JONATHAN S ILOWITE, NPI 1356403364, CMS profile ID 288011, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1356403364?year=2020&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
1 matching record · $1,849.01 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–1 of 1.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,849.01 | 07/08/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720515093 | CMS |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2020 | $1,849.01 | 1 |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2020
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2020
- Generated from
- OP_DTL_GNRL_PGYR2020_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $55,453.36 | 13 |
| PY2024 | Principal investigator | $96,271.40 | 77 |
| PY2023 | Principal investigator | $77,314.74 | 41 |
| PY2022 | Principal investigator | $92,991.92 | 43 |
| PY2021 | Principal investigator | $201,603.87 | 45 |
| PY2020 | Principal investigator | $61,126.56 | 5 |
| PY2019 | Principal investigator | $116,156.75 | 4 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
77 records in PY2024
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $285.69 | 12/31/2024 | Non-covered Recipient Entity BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK | A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease COPD with a History of COPD Exacerbations OBERON | No dispute reported | 06/30/2026 | 1155802514 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $937.80 | 12/11/2024 | Non-covered Recipient Entity BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1156002331 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,248.20 | 11/06/2024 | Non-covered Recipient Entity BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1127537980 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,396.80 | 10/04/2024 | Non-covered Recipient Entity BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1127537974 |
| Principal investigator 1 | Insmed, Inc. | $1,360.00 | 10/01/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067596826 |
| Principal investigator 1 | Insmed, Inc. | $1,500.00 | 10/01/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067607558 |
| Principal investigator 1 | Insmed, Inc. | $1,500.00 | 10/01/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067607560 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $945.00 | 09/06/2024 | Non-covered Recipient Entity BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1127537978 |
| Principal investigator 1 | Insmed, Inc. | $10.20 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067591330 |
| Principal investigator 1 | Insmed, Inc. | $241.40 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067591332 |
| Principal investigator 1 | Insmed, Inc. | $236.78 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067591334 |
| Principal investigator 1 | Insmed, Inc. | $245.62 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067591336 |
| Principal investigator 1 | Insmed, Inc. | $229.98 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067591338 |
| Principal investigator 1 | Insmed, Inc. | $241.40 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067591340 |
| Principal investigator 1 | Insmed, Inc. | $69.36 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067591342 |
| Principal investigator 1 | Insmed, Inc. | $160.48 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067591344 |
| Principal investigator 1 | Insmed, Inc. | $69.36 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067591346 |
| Principal investigator 1 | Insmed, Inc. | $81.06 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067591348 |
| Principal investigator 1 | Insmed, Inc. | $242.08 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067591350 |
| Principal investigator 1 | Insmed, Inc. | $338.64 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067591352 |
| Principal investigator 1 | Insmed, Inc. | $242.08 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067591354 |
| Principal investigator 1 | Insmed, Inc. | $6.12 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067596808 |
| Principal investigator 1 | Insmed, Inc. | $81.06 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067596810 |
| Principal investigator 1 | Insmed, Inc. | $242.08 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067596812 |
| Principal investigator 1 | Insmed, Inc. | $20.40 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067596814 |
| Principal investigator 1 | Insmed, Inc. | $4.76 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067596816 |
| Principal investigator 1 | Insmed, Inc. | $245.62 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067596818 |
| Principal investigator 1 | Insmed, Inc. | $69.36 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067596820 |
| Principal investigator 1 | Insmed, Inc. | $236.78 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067596822 |
| Principal investigator 1 | Insmed, Inc. | $242.08 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067596824 |
| Principal investigator 1 | Insmed, Inc. | $20.40 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067602154 |
| Principal investigator 1 | Insmed, Inc. | $160.48 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067602156 |
| Principal investigator 1 | Insmed, Inc. | $81.06 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067602158 |
| Principal investigator 1 | Insmed, Inc. | $69.36 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067602160 |
| Principal investigator 1 | Insmed, Inc. | $208.08 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067602162 |
| Principal investigator 1 | Insmed, Inc. | $81.06 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067602164 |
| Principal investigator 1 | Insmed, Inc. | $208.08 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067602166 |
| Principal investigator 1 | Insmed, Inc. | $338.64 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067602168 |
| Principal investigator 1 | Insmed, Inc. | $229.98 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067607538 |
| Principal investigator 1 | Insmed, Inc. | $81.06 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067607540 |
| Principal investigator 1 | Insmed, Inc. | $212.30 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067607542 |
| Principal investigator 1 | Insmed, Inc. | $81.06 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067607544 |
| Principal investigator 1 | Insmed, Inc. | $199.38 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067607546 |
| Principal investigator 1 | Insmed, Inc. | $338.64 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067607548 |
| Principal investigator 1 | Insmed, Inc. | $6.80 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067607550 |
| Principal investigator 1 | Insmed, Inc. | $338.64 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067607552 |
| Principal investigator 1 | Insmed, Inc. | $195.16 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067607554 |
| Principal investigator 1 | Insmed, Inc. | $195.16 | 09/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067607556 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,548.70 | 08/14/2024 | Non-covered Recipient Entity BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1127521840 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,247.40 | 07/08/2024 | Non-covered Recipient Entity BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1127521838 |
| Principal investigator 1 | Insmed, Inc. | $105.26 | 06/28/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067591328 |
| Principal investigator 1 | Insmed, Inc. | $37.94 | 06/28/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067596802 |
| Principal investigator 1 | Insmed, Inc. | $37.94 | 06/28/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067596804 |
| Principal investigator 1 | Insmed, Inc. | $37.94 | 06/28/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067596806 |
| Principal investigator 1 | Insmed, Inc. | $37.94 | 06/28/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067602148 |
| Principal investigator 1 | Insmed, Inc. | $105.26 | 06/28/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067602150 |
| Principal investigator 1 | Insmed, Inc. | $37.94 | 06/28/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067602152 |
| Principal investigator 1 | Insmed, Inc. | $37.94 | 06/28/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067607532 |
| Principal investigator 1 | Insmed, Inc. | $105.26 | 06/28/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067607534 |
| Principal investigator 1 | Insmed, Inc. | $105.26 | 06/28/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067607536 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $970.00 | 06/21/2024 | Non-covered Recipient Entity BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1127521834 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $11,444.00 | 06/21/2024 | Non-covered Recipient Entity BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1127537968 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,739.40 | 06/14/2024 | Non-covered Recipient Entity BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1127537964 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,579.20 | 05/08/2024 | Non-covered Recipient Entity BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1127521842 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,839.50 | 04/15/2024 | Non-covered Recipient Entity BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1127521844 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,250.00 | 04/05/2024 | Non-covered Recipient Entity BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1127537962 |
| Principal investigator 1 | Insmed, Inc. | $400.00 | 04/02/2024 | Non-covered Recipient Entity The Feinstein Institutes for Medical Research | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | No dispute reported | 06/30/2026 | 1067602146 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,272.40 | 03/13/2024 | Non-covered Recipient Entity BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1127537966 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,144.00 | 03/06/2024 | Non-covered Recipient Entity BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1127537972 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,642.00 | 03/04/2024 | Non-covered Recipient Entity Biomedical Research Alliance Of New York LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation | No dispute reported | 06/30/2026 | 1128717979 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $925.00 | 02/09/2024 | Non-covered Recipient Entity BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1127521836 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $5,442.00 | 02/07/2024 | Non-covered Recipient Entity BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK | Phase III study is to evaluate the efficacy and safety of Tozorakimab MEDI3506 Dose 1 and Dose 2 administered subcutaneously SC in adult participants with symptomatic COPD and history of 2 moderate or 1 severe exacerbation of COPD in the previous 12 months | No dispute reported | 06/30/2026 | 1110846425 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,859.10 | 02/02/2024 | Non-covered Recipient Entity BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1127537976 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $925.00 | 01/29/2024 | Non-covered Recipient Entity Biomedical Research Alliance Of New York LLC | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation | No dispute reported | 06/30/2026 | 1128717963 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $9,738.69 | 01/24/2024 | Non-covered Recipient Entity BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK | The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod | No dispute reported | 06/30/2026 | 1110834929 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $9,955.80 | 01/12/2024 | Non-covered Recipient Entity BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1127537970 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $925.00 | 01/10/2024 | Non-covered Recipient Entity BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1127537960 |